Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 3/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.41 |
| ▸ | NAMPT | P43490 | 8/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718121 | 0.79 | ITGB3 (0.48) | NAMPTITGB1 | |
| SCHEMBL4715035 | 0.77 | NAMPT (0.43) | GRIN1GRIN2AGRIN2BNAMPTPRMT5 | |
| SCHEMBL4718126 | 0.75 | ITGB3 (0.46) | ITGB1 | |
| SCHEMBL4716886 | 0.75 | ITGB1 (0.42) | ITGB1ITGA5 | |
| SCHEMBL4715244 | 0.73 | ITGB1 (0.40) | ITGB1ITGA5PRMT5WDR77DRD2 | |
| SCHEMBL17551505 | 0.72 | NPY5R (0.59) | NAMPTEPHX2 | |
| SCHEMBL4716851 | 0.67 | DPP4 (0.51) | ITGB1 | |
| SCHEMBL28522930 | 0.66 | MEN1 (0.46) | NAMPT | |
| SCHEMBL14222776 | 0.65 | GRIN1 (0.49) | GRIN1GRIN2AGRIN2BNAMPTPRMT5 | |
| SCHEMBL27726454 | 0.65 | ACE (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |